Citations

Clear

382 citation(s) found for "Shapiro, R".

Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial.
Shergill, Ardaman , Liao, Chih-Yi, Baghdadi, Tareq Al, Feldman, Diane, Shroff, Rachna T. , Baghdadi, Tareq Al , Liao, Chih‐Yi , Elsaid, Mohamed I , Ji, Yan , Feldman, Diane, George, Suzanne , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A. , Berg, Stephanie , Schwartz, Gary K. , Münster, Pamela N. , Bekaii‐Saab, Tanios , Abou‐Alfa, Ghassan K. , Shapiro, Geoffrey I.

Mayo Clinic

Journal of Clinical Oncology | July 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS4196-TPS4196

10.1200/jco.2024.42.16_suppl.tps4196 Get It

TPS4196 Background: Advanced BTC patients have poor prognosis. Up to 40% of BTCs have KRAS mutations and are associated with worse overall survival (OS). With a median OS of 7.7 months in KRAS wild-type compared to 1.7 months in KRAS mutated disease, these alterations are independent poor prognostic factors in BTC. Gemcitabine and cisplatin (GC) with or without immunotherapy are often used as 1st-line therapies. However, there is a lack of data on best 2nd-line regimens. mFOLFOX6 (5-fluorouracil [5-FU], leucovorin [LV], oxaliplatin) or liposomal irinotecan+5-FU+LV are options when no biomarkers are found (e.g., MSI-H, BRAFV600E, FGFR-fusions, IDH1-mutation, HER2-overexpression). Prior studies do not demonstrate benefit with MEK inhibitors (MEKi), but none of the studies had biomarker selection. Pre-clinical studies in BTC cell lines suggest synergy between MEKi and 5-FU. Thymidylate synthase (TS )levels induced by 5-FU are downregulated by addition of binimetinib. Early clinical studies show safety and tolerance of this combination. In this study, we will evaluate if the combination of mFOLFOX6+binimetinib improves OS for patients with BTC and MAPK mutations compared to mFOLFOX6 alone in 2nd-line therapy. Methods: EAY191-A6 is a treatment study arm of the NCI ComboMATCH master registration trial EAY191. The A6 trial has a randomized phase II design, enrolling a maximum of 66 patients. Patients with any MAPK pathway mutations except those with available therapies will be eligible. Patient must first enroll to the EAY191 master trial. Local molecular results may be used for enrollment. Submission of tissue at baseline is mandatory. Eligible patients will be randomized 1:1 to mFOLFOX6 vs mFOLFOX6 + binimetinib (45 mg oral twice a day every 14 days). Stratification factors include location and stage of disease. Primary efficacy analysis will compare OS in the intent-to-treat population. If the observed hazard ratio (HR) of experimental arm vs standard of care is < 0.545 (corresponding to an observed increase in OS by 5 months or longer), experimental treatment will be considered superior. An interim futility analysis at 50% of expected events will be conducted. If the observed HR is ≥ 1, experimental treatment will not be considered superior, and accrual maybe suspended. Secondary endpoints include progression-free survival, objective response rate, duration of response, disease control rate and toxicity of treatments. Exploratory objectives include prognostic modeling, correlations of genomic alterations with response or resistance and use of machine learning for outcome prediction. This study is active and open to accrual. Clinical trial information: NCT05564403 .
Evaluation of Platelet-rich Plasma and Microneedling for Facial Skin Rejuvenation
Zawawi, Suha, Hochwald, Alexander , Arthurs, Jennifer R. , Tolaymat, Leila , Bruce, Alison J., Pincelli, Thais P, Hochwald, Alexander P, Arthurs, Jennifer, Bruce, Alison, Pincelli, Thaís , Shapiro, Shane A. , Heckman, Michael G.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | May 20, 2024 | Volume: 12 | Issue: 5 | Pages: e5829

10.1097/gox.0000000000005829 | PMID 38798929 Get It

Background: The regenerative properties of platelet growth factors make platelet-rich-plasma (PRP) an attractive modality for treatment of aging skin. The main objective of this study was to determine efficacy and safety of PRP injections and microneedling compared with saline injections in women with aging skin of the face. Methods: In this prospective, randomized clinical trial, 18 women with facial aging were randomized to receive either PRP injections to the unilateral face and saline injections to the contralateral side, or vice versa. Microneedling was performed after injections on the entire face. Physician assessment, photographs, and treatment satisfaction questionnaires were used for outcome assessment at baseline and 16- and 24-week follow-ups. Results: There was no evidence of improvement and suggestion of worsening in skin laxity and rhytides from baseline to weeks 4, 16, and 24 for PRP and saline (all P ≤ 0.004) and no notable difference in skin roughness between baseline and follow-up time points for PRP or saline (all P ≥ 0.19). The degree of change in skin laxity, rhytides, and skin roughness from baseline to follow-up time points was similar for PRP and saline. All patients experienced some degree of pain/discomfort and burning/stinging sensation at treatment weeks 4, 8, and 12 for both saline and PRP. Conclusions: PRP injections did not seem to be effective for treatment of aging skin of the face in women, with no notable macroscopic improvement in appearance when compared with baseline or saline injections. Advanced age of study participants (>45 years) and less-sensitive methods of evaluation may be potential contributing factors to the lack of detected response.
Tonic Inhibition of Sodium Reabsorption by Na+/K+-ATPase in the Renal Proximal Tubule
Mukherji, Shreya T. , Brambilla, Luca , Mayes, Isabella, Kutz, Laura C. , McDermott, Jeff P., Shapiro, Joseph I., Blanco, Gustavo , Xie, Zijian , Pierre, Sandrine V. , McDermott, Jeffrey P. , Haller, Steven T. , Romero, Michael F. , Liu, Jiang , Shapiro, Joseph I.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 656-656

10.1681/asn.20203110s1656b Get It

Non–Small Cell Lung Cancer, Version 4.2024
Riely, Gregory J. , Wood, Douglas E. , Ettinger, David S. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , DeCamp, Malcolm M., Desai, Aakash , Dilling, Thomas J. , Dowell, Jonathan E. , Durm, Gregory A. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Owen, Dawn , Patel, Sandip Pravin , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hang, Lisa, Desai, Aakash P , Bharat, Ankit , Chang, Joe Y. , Chirieac, Lucian R. , Grotz, Travis E. , Juloori, Aditya , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Owen, Dwight H , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 16, 2024 | Volume: 22 | Issue: 4 | Pages: 249-274

10.6004/jnccn.2204.0023 | PMID 38754467 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers.
A Phase 3, 2-part, Open-label, Multicenter Study to Evaluate the Safety, and Efficacy of Liposomal Treprostinil Inhalation Suspension (l606) in Subjects With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung
Habib, N. , Jaramillo, R. Restrepo, Shapiro, Shelley, Galloway, Ashley L. , Kan, Peter , Saggar, Rajeev, Shapiro, Shelley, Burger, Charles D. , Patel, Shardool A. , Kan, P.

Mayo Clinic

D105. BALBOA PARK EXPLORERS: TRANSLATIONAL SCIENCE AND EPIDEMIOLOGY IN PH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7368-A7368

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7368 Get It

Abstract 342: Comparison of Fractional Flow Reserve (FFR) and Cardiac Stress Testing in Prediction of Coronary Ischemia
Shahrivari, Mahan, Kurklinsky, Andrew K., Levy, Michael , Shapiro, Brian P. , Moussa, Issam , Kumar, Preetham

Mayo Clinic

Circulation | April 23, 2024 | Volume: 128 | Issue: suppl_22 | Pages: No page available

10.1161/circ.128.suppl_22.a342 Get It

Introduction: Clinical outcomes of FFR-guided PCI have been superior to those of angiographically guided PCI, with or without prior cardiac stress testing. Based on these findings, we hypothesized that the accuracy of stress testing is inferior to that of FFR in determining the physiologic significance of angiographic coronary artery disease. Method: To that end, we studied 243 consecutive patients who underwent coronary angiography and FFR assessment between September 2010 and April 2013 at Mayo Clinic, Florida. Out of this group, we excluded 143 patients due to absence of stress testing in the preceding 6 months. We assessed demographics, coronary risk factors, symptoms, stress test variables, angiographic data, and FFR measurements. FFR values ≤0.80 were considered to be positive for ischemia. We evaluated the diagnostic performance of stress testing vs. FFR. Result: Out of the 100 patients included in the study, FFR was measured in the Left Main coronary artery in 3(3%), in the Left Anterior Descending artery (LAD) in 67(67%), in the left circumflex territory in 11(11%), in the Right Coronary Artery (RCA) in 18(18%). The diagnostic performance of stress testing vs. FFR is summarized in the table, with regards to presence of ischemia in any vascular territory and with regards to a specific vascular territory. Conclusion: Compared to FFR, cardiac stress testing has reasonable NPV but poor PPV in determining the presence of absence of overall ischemia in a given patient. Most concerning, however, is that stress testing has poor PPV and NPV when used to determine the site of ischemia in a specific vascular territory.
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
Park, Han-Sol , Yin, Anna , Barranta, Caelan, Caputo, Christopher , Sachithanandham, Jaiprasath , Li, Maggie , Yoon, Steve, Sitaras, Ioannis , Jedlicka, Anne , Eby, Yolanda , Ram, Malathi , Fernández, Reinaldo E. , Baker, Owen R. , Fukuta, Yuriko , Patel, Bela , Heath, Sonya L. , Spivak, Emily S , Huamán, Moisés A. , Blair, Janis E. , Gerber, Jonathan M. , Petrini, Joann, Broderick, Patrick , Rausch, William, Cordisco, Marie Elena , Hammel, Jean, Greenblatt, Benjamin, Cluzet, Valerie , Cruser, Daniel, Oei, Kevin , Abinante, Matthew, Hammitt, Laura L. , Forthal, Donald N. , Cachay, Edward R. , Marshall, Christi E., Lane, Karen , McBee, Nichol , Gawad, Amy L., Karlen, Nicky, Singh, Atika, Jabs, Douglas A. , Shade, David , Lau, Bryan , Ehrhardt, Stephan , Baksh, Sheriza , Ou, Jiangda , Na, Yu Bin , Knoll, Maria Deloria , Ornelas-Gatdula, Elysse, Gniadek, Thomas J. , Wu, Jinke, Ndahiro, Nelson , Betenbaugh, Michael J. , Ziman, Alyssa , Bloch, Evan M. , Laeyendecker, Oliver , Ziman, Alyssa , Huaman, Moises A , Laeyendecker, Oliver , Lee, John S. , Shenoy, Aarthi , Mosnaim, Giselle S , Levine, Adam C , Meisenberg, Barry R. , Anjan, Shweta , Currier, Judith S. , Paxton, James H , Sutcliffe, Catherine G , Zand, Martin S. , Raval, Jay S. , Kassaye, Seble , Yarava, Anusha , Ford, Daniel E , Appel, Lawrence J. , Shapiro, Janna R. , Arroyo‐Currás, Netzahualcóyotl , Caturegli, Patrizio , Hanley, Daniel F. , Casadevall, Arturo , Shoham, Shmuel , Gebo, Kelly A , Tobian, Aaron A.R. , Pekosz, Andrew , Klein, Sabra L , Sullivan, David

Mayo Clinic

JCI Insight | April 23, 2024 | Volume: 9 | Issue: 8 | Pages: No page available

10.1172/jci.insight.178460 | PMID 38483534 Get It

BACKGROUND COVID-19 convalescent plasma (CCP) virus-specific antibody levels that translate into recipient posttransfusion antibody levels sufficient to prevent disease progression are not defined. METHODS This secondary analysis correlated donor and recipient antibody levels to hospitalization risk among unvaccinated, seronegative CCP recipients within the outpatient, double-blind, randomized clinical trial that compared CCP to control plasma. The majority of COVID-19 CCP arm hospitalizations (15/17, 88%) occurred in this unvaccinated, seronegative subgroup. A functional cutoff to delineate recipient high versus low posttransfusion antibody levels was established by 2 methods: (i) analyzing virus neutralization–equivalent anti–Spike receptor-binding domain immunoglobulin G (anti-S-RBD IgG) responses in donors or (ii) receiver operating characteristic (ROC) curve analysis. RESULTS SARS-CoV-2 anti–S-RBD IgG antibody was volume diluted 21.3-fold into posttransfusion seronegative recipients from matched donor units. Virus-specific antibody delivered was approximately 1.2 mg. The high-antibody recipients transfused early (symptom onset within 5 days) had no hospitalizations. A CCP-recipient analysis for antibody thresholds correlated to reduced hospitalizations found a statistical significant association between early transfusion and high antibodies versus all other CCP recipients (or control plasma), with antibody cutoffs established by both methods-donor-based virus neutralization cutoffs in posttransfusion recipients (0/85 [0%] versus 15/276 [5.6%]; P = 0.03) or ROC-based cutoff (0/94 [0%] versus 15/267 [5.4%]; P = 0.01). CONCLUSION In unvaccinated, seronegative CCP recipients, early transfusion of plasma units in the upper 30% of study donors’ antibody levels reduced outpatient hospitalizations. High antibody level plasma units, given early, should be reserved for therapeutic use. TRIAL REGISTRATION ClinicalTrials.gov NCT04373460. FUNDING Department of Defense (W911QY2090012); Defense Health Agency; Bloomberg Philanthropies; the State of Maryland; NIH (3R01AI152078-01S1, U24TR001609-S3, 1K23HL151826NIH); the Mental Wellness Foundation; the Moriah Fund; Octapharma; the Healthnetwork Foundation; the Shear Family Foundation; the NorthShore Research Institute; and the Rice Foundation.
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
Konstantinopoulos, Panagiotis A. , Cheng, Su–Chun, Lee, Elizabeth K. , Costa, Alexandre André Balieiro Anastácio da , Gulhan, D. , Hendrickson, Andrea E. Wahner , Kochupurakkal, Bose , Kolin, David L. , Kohn, Elise C. , Liu, Joyce F. , Penson, Richard T. , Stover, Elizabeth H. , Curtis, Jennifer, Sawyer, Hannah , Polak, Madeline , D’Andrea, Alan D. , Matulonis, Ursula A. , da Costa, Alexandre André B A , Gulhan, Doga , Wahner Hendrickson, Andrea E , D'Andrea, Alan , Shapiro, Geoffrey I , Matulonis, Ursula A , Konstantinopoulos, Panagiotis A , Chowdhury, Dipanjan , Färkkilä, Anniina , Shapiro, Geoffrey I.

Mayo Clinic

JCO Precision Oncology | April 18, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po.23.00635 | PMID 38635934 Get It

PURPOSE The multicenter, open-label, randomized phase 2 NCI-9944 study ( NCT02595892 ) demonstrated that addition of ATR inhibitor (ATRi) berzosertib to gemcitabine increased progression-free survival (PFS) compared to gemcitabine alone (hazard ratio [HR]=0.57, one-sided log-rank P = .044, which met the one-sided significance level of 0.1 used for sample size calculation). METHODS We report here the final overall survival (OS) analysis and biomarker correlations (ATM expression by immunohistochemistry, mutational signature 3 and a genomic biomarker of replication stress) along with post-hoc exploratory analyses to adjust for crossover from gemcitabine to gemcitabine/berzosertib. RESULTS At the data cutoff of January 27, 2023 (>30 months of additional follow-up from the primary analysis), median OS was 59.4 weeks with gemcitabine/berzosertib versus 43.0 weeks with gemcitabine alone (HR 0.79, 90% CI 0.52 to 1.2, one-sided log-rank P = .18). An OS benefit with addition of berzosertib to gemcitabine was suggested in patients stratified into the platinum-free interval ≤3 months (N = 26) subgroup (HR, 0.48, 90% CI 0.22 to 1.01, one-sided log-rank P =.04) and in patients with ATM-negative/low (N = 24) tumors (HR, 0.50, 90% CI 0.23 to 1.08, one-sided log-rank P = .06). CONCLUSION The results of this follow-up analysis continue to support the promise of combined gemcitabine/ATRi therapy in platinum resistant ovarian cancer, an active area of investigation with several ongoing clinical trials.
Rag-GTPase-TFEB/TFE3 axis controls B cell mitochondrial fitness and humoral immunity independent of mTORC1
Zeng, Hu , Zhu, Xingxing , Wu, Yue , Li, Yanfeng , Chen, Yin , Raybuck, Ariel , Billadeau, Daniel D. , Shapiro, Virginia Smith , Zhu, Xingxing , Wu, Y , Watzlawik, Jens O. , Chen, Yin Maggie, Shapiro, Virginia S , Sun, Jie , Zeng, Hu , Zhou, Xian , Springer, Wolfdieter , Sun, Jie , Boothby, Mark Robin

Mayo Clinic

No container title available | March 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3957355/v1 | PMID 38585731 Get It

Abstract During the humoral immune response, B cells undergo rapid metabolic reprogramming with a high demand for nutrients, which are vital to sustain the formation of the germinal centers (GCs). Rag-GTPases sense amino acid availability to modulate the mechanistic target of rapamycin complex 1 (mTORC1) pathway and suppress transcription factor EB (TFEB) and transcription factor enhancer 3 (TFE3), members of the microphthalmia (MiT/TFE) family of HLH-leucine zipper transcription factors. However, how Rag-GTPases coordinate amino acid sensing, mTORC1 activation, and TFEB/TFE3 activity in humoral immunity remains undefined. Here, we show that B cell-intrinsic Rag-GTPases are critical for the development and activation of B cells. RagA/RagB deficient B cells fail to form GCs, produce antibodies, and generate plasmablasts in both T-dependent (TD) and T-independent (TI) humoral immune responses. Deletion of RagA/RagB in GC B cells leads to abnormal dark zone (DZ) to light zone (LZ) ratio and reduced affinity maturation. Mechanistically, the Rag-GTPase complex constrains TFEB/TFE3 activity to prevent mitophagy dysregulation and maintain mitochondrial fitness in B cells, which are independent of canonical mTORC1 activation. TFEB/TFE3 deletion restores B cell development, GC formation in Peyer’s patches and TI humoral immunity, but not TD humoral immunity in the absence of Rag-GTPases. Collectively, our data establish Rag-GTPase-TFEB/TFE3 axis as an mTORC1 independent mechanism to coordinating nutrient sensing and mitochondrial metabolism in B cells.